Therapeutic plasma exchange in multiple sclerosis patients with an aggressive relapse: an observational analysis in a high-volume center
Abstract An evidence-based treatment for a Multiple Sclerosis (MS) relapse is an intravenous administration of 3–5 g of Methylprednisolone. In case of insufficient effect or corticosteroids intolerance, the therapeutic plasma exchange (TPE) is indicated. To assess the clinical effect of TPE in treat...
Main Authors: | R. Bunganic, S. Blahutova, K. Revendova, O. Zapletalova, P. Hradilek, R. Hrdlickova, A. Ganesh, Z. Cermakova, M. Bar, O. Volny |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-23356-w |
Similar Items
-
Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis
by: Martin Lachnit, et al.
Published: (2024-03-01) -
Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis
by: Pavel Hradilek, et al.
Published: (2023-03-01) -
Analysis of cerebrospinal fluid cells by flow cytometry: Comparison to conventional cytology
by: David Zeman, et al.
Published: (2023-06-01) -
Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis
by: Alsahebfosoul Fereshteh, et al.
Published: (2017-01-01) -
Efficacy of cascade plasmapheresis in comparison with conventional therapeutic plasma exchange for relapsed atypical hemolytic uremic syndrome: A case report
by: Ashwinkumar Vaidya, et al.
Published: (2022-01-01)